Hepatitis B (Infectious Disease) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B – Drugs In Development, 2021, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 46, 36, 4, 102, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 8 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Abhelix LLC

Ai-biopharma SAS

AiCuris AG

Akshaya Bio Inc

Aligos Therapeutics Inc

AlloVir Inc

AlphaMab Co Ltd

Alphamab Oncology

Altimmune Inc

Antios Therapeutics Inc

Apros Therapeutics Inc

Arbutus Biopharma Corp

Arcturus Therapeutics Holdings Inc

Ascentage Pharma Group International

Ascletis Pharma Inc

Assembly Biosciences Inc

Atea Pharmaceuticals Inc

Aucta Pharmaceuticals LLC

Auro Vaccines LLC

Avalia Immunotherapies Ltd

Beijing Advaccine Biotechnology Company Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Beijing Minhai Biotechnology Co Ltd

Benitec Biopharma Inc

Biological E Ltd

Biomics Biopharma Ltd

BioNet-Asia Co Ltd

Biotron Ltd

Bolder Biotechnology Inc

Bonac Corp

Brandenburg Antiinfektiva GmbH

Brickell Biotech Inc

BrightGene Bio-Medical Technology Co Ltd

Bukwang Pharmaceutical Co Ltd

Cadila Healthcare Ltd

CaroGen Corp

Chengdu Hyperway Pharmaceuticals

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Chong Kun Dang Pharmaceutical Corp

Chongqing Jiachen Biotechnology Ltd

Chongqing Zhifei Biological Products Co Ltd

Cinkate Corp

ClearB Therapeutics Inc

CN Bio Innovations Ltd

Cocrystal Pharma Inc

Collaborations Pharmaceuticals Inc

ConserV Bioscience Ltd

Curigin Co Ltd

CyTuVax BV

DelSiTech Ltd

Dicerna Pharmaceuticals Inc

Dong-A ST Co Ltd

Door Pharmaceuticals LLC

Drug Farm Inc

Elixiron Immunotherapeutics Inc

Enanta Pharmaceuticals Inc

Enochian Biosciences Inc

Enyo Pharma SA

Etna Biotech Srl

Evotec SE

Evrys Bio

Excision BioTherapeutics Inc

F. Hoffmann-La Roche Ltd

Finch Therapeutics Group Inc

FortuneRock (China) Ltd

Fujian Cosunter Pharmaceutical Co Ltd

GC Pharma

GemVax & KAEL Co Ltd

GeneCure Biotechnologies LLC

GeneLancet Biosciences Inc

GeneScience Pharmaceuticals Co Ltd

GeoVax Labs Inc

Gilead Sciences Inc

Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd

GlaxoSmithKline Plc

Golden Biotechnology Corp

Guangdong East Sunshine Pharmaceutical Co Ltd

Guangxi Hebabiz Pharmaceutical Co Ltd

Guangzhou Yipinhong Pharmaceutical Co Ltd

HDT Bio Corp

HEC Pharma Co Ltd

Hepion Pharmaceuticals Inc

Huahui Anjian (Beijing) Biotechnology Co Ltd

ImmuneMed Inc

Immunocore Holdings Plc

Indaptus Therapeutics Inc

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

ISA Pharmaceuticals BV

ISR Immune System Regulation Holding AB

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Jubilant Therapeutics Inc

Kainos Medicine Inc

KinoPharma Inc

Kyung Dong Co Ltd

LG Chem Ltd

Ligand Pharmaceuticals Inc

Lion TCR Pte Ltd

Max Biopharma Inc

Maxwell Biosciences Inc

METiS Pharmaceuticals

Microbiotix Inc

Nanjing Yuandasai Weixin Biomedical Co Ltd

Novo Medi Sciences Pvt Ltd

Nucorion Pharmaceuticals Inc

Oncolys BioPharma Inc

Palisades Therapeutics

Palo Alto pharmaceuticals Inc

PharmaEssentia Corp

Precigen Inc

Precision Biosciences Inc

Profarma

Prosit Sole Biotechnology (Beijing) Co Ltd

Protheragen Inc

Qilu Pharmaceutical Co Ltd

Regeneron Pharmaceuticals Inc

Regulus Therapeutics Inc

Replicor Inc

Resonance Health Ltd

Rodos BioTarget GmbH

Romark Laboratories LC

Samjin Pharm Co Ltd

Sclnow Biotechnology Co Ltd

SFA Therapeutics LLC

Shanghai Ark Biopharmaceutical Co Ltd

Shanghai Henlius Biotech Inc

Shanghai HEP Pharmaceutical Co Ltd

Shanghai Zhimeng Biopharma Inc

Shantha Biotechnics Pvt Ltd

Shenzhen BinDeBio Ltd

Shionogi & Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Silverback Therapeutics Inc

Sinovac Biotech Ltd

Sirnaomics Inc

SL VaxiGen Inc

SQZ Biotechnologies Co

Staidson BioPharma Inc

Statera BioPharma Inc

Suzhou Ribo Life Sciences Co Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

Taiga Biotechnologies Inc

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

TeneoBio Inc

Tetranov International Inc

Tevogen Bio Inc

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Transgene SA

UBI Pharma Inc

Vaccitech plc

Vaxart Inc

Vaxine Pty Ltd

VBI Vaccines Inc

VenatoRx Pharmaceuticals Inc

Vir Biotechnology Inc

Viravaxx AG

Viriom Inc

Virion Therapeutics LLC

Virocovax

ViroStatics SRL

VLP Biotech Inc

Xi'An Yufan Biotechnology Co Ltd

Yisheng Biopharma Co Ltd

Zelluna Immunotherapy AS

Zhengda Tianqing Pharmaceutical Group Co Ltd

Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

Introduction

Hepatitis B - Overview

Hepatitis B - Therapeutics Development

Hepatitis B - Therapeutics Assessment

Hepatitis B - Companies Involved in Therapeutics Development

Hepatitis B - Drug Profiles

Hepatitis B - Dormant Projects

Hepatitis B - Discontinued Products

Hepatitis B - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Hepatitis B, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hepatitis B – Pipeline by Abhelix LLC, 2021

Hepatitis B – Pipeline by Ai-biopharma SAS, 2021

Hepatitis B – Pipeline by AiCuris AG, 2021

Hepatitis B – Pipeline by Akshaya Bio Inc, 2021

Hepatitis B – Pipeline by Aligos Therapeutics Inc, 2021

Hepatitis B – Pipeline by AlloVir Inc, 2021

Hepatitis B – Pipeline by AlphaMab Co Ltd, 2021

Hepatitis B – Pipeline by Alphamab Oncology, 2021

Hepatitis B – Pipeline by Altimmune Inc, 2021

Hepatitis B – Pipeline by Antios Therapeutics Inc, 2021

Hepatitis B – Pipeline by Apros Therapeutics Inc, 2021

Hepatitis B – Pipeline by Arbutus Biopharma Corp, 2021

Hepatitis B – Pipeline by Arcturus Therapeutics Holdings Inc, 2021

Hepatitis B – Pipeline by Ascentage Pharma Group International, 2021

Hepatitis B – Pipeline by Ascletis Pharma Inc, 2021

Hepatitis B – Pipeline by Assembly Biosciences Inc, 2021

Hepatitis B – Pipeline by Atea Pharmaceuticals Inc, 2021

Hepatitis B – Pipeline by Aucta Pharmaceuticals LLC, 2021

Hepatitis B – Pipeline by Auro Vaccines LLC, 2021

Hepatitis B – Pipeline by Avalia Immunotherapies Ltd, 2021

Hepatitis B – Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021

Hepatitis B – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, 2021

Hepatitis B – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021

Hepatitis B – Pipeline by Benitec Biopharma Inc, 2021

Hepatitis B – Pipeline by Biological E Ltd, 2021

Hepatitis B – Pipeline by Biomics Biopharma Ltd, 2021

Hepatitis B – Pipeline by BioNet-Asia Co Ltd, 2021

Hepatitis B – Pipeline by Biotron Ltd, 2021

Hepatitis B – Pipeline by Bolder Biotechnology Inc, 2021

Hepatitis B – Pipeline by Bonac Corp, 2021

Hepatitis B – Pipeline by Brandenburg Antiinfektiva GmbH, 2021

Hepatitis B – Pipeline by Brickell Biotech Inc, 2021

Hepatitis B – Pipeline by BrightGene Bio-Medical Technology Co Ltd, 2021

Hepatitis B – Pipeline by Bukwang Pharmaceutical Co Ltd, 2021

Hepatitis B – Pipeline by Cadila Healthcare Ltd, 2021

Hepatitis B – Dormant Projects, 2021

Hepatitis B – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hepatitis B, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports